Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jan 25;1(1):CD007716.
doi: 10.1002/14651858.CD007716.pub4.

Macrolides for diffuse panbronchiolitis

Xiufang Lin  1 , Jing Lu, Ming Yang, Bi Rong Dong, Hong Mei Wu
Affiliations

Macrolides for diffuse panbronchiolitis

Xiufang Lin et al. Cochrane Database Syst Rev. .

Abstract

Background: Diffuse panbronchiolitis (DPB) is a chronic airways disease predominantly affecting East Asians. Macrolides, a class of antibiotics, have been used as the main treatment for DPB, based on evidence from retrospective and non-randomised studies.

Objectives: To assess the efficacy and safety of macrolides for DPB.

Search methods: We searched CENTRAL (2014, Issue 6), MEDLINE (1966 to July week 1, 2014), EMBASE (1974 to July 2014), Chinese Biomedical Literature Database (CBM) (1978 to July 2014), China National Knowledge Infrastructure (CNKI) (1974 to July 2014), KoreaMed (1997 to July 2014) and Database of Japana Centra Revuo Medicina (1983 to July 2014).

Selection criteria: Randomised controlled trials (RCTs) or quasi-RCTs assessing the effect of macrolides for DPB.

Data collection and analysis: Two review authors independently assessed study quality and subsequent risk of bias according to The Cochrane Collaboration's tool for assessing risk of bias. The primary outcomes were five-year survival rate, lung function and clinical response. We used risk ratios (RR) for individual trial results in the data analysis and measured all outcomes with 95% confidence intervals (CI).

Main results: Only one RCT (19 participants) with significant methodological limitations was included in this review. It found that the computerised tomography images of all participants treated with a long-term, low-dose macrolide (erythromycin) improved from baseline, while the images of 71.4% of participants in the control group (with no treatment) worsened and 28.6% remained unchanged. Adverse effects were not reported. This review was previously published in 2010 and 2013. For this 2014 update, we identified no new trials for inclusion or exclusion.

Authors' conclusions: There is little evidence for macrolides in the treatment of DPB. We are therefore unable to make any new recommendations. It may be reasonable to use low-dose macrolides soon after diagnosis is made and to continue this treatment for at least six months, according to current guidelines.

PubMed Disclaimer

Conflict of interest statement

Xiufang Lin: none known Jing Lu: none known Ming Yang: none known Bi Rong Dong: none known Hong Mei Wu: none known

Figures

1
1
'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
2
2
'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.
3
3
Forest plot of comparison: 1 Erythromycin versus no treatment, outcome: 1.1 The rate of improvement in CT images.
4
4
Forest plot of comparison: 1 Erythromycin versus no treatment, outcome: 1.2 The rate of progress in CT images.
1.1
1.1. Analysis
Comparison 1 Erythromycin versus no treatment, Outcome 1 The rate of improvement in CT images.
1.2
1.2. Analysis
Comparison 1 Erythromycin versus no treatment, Outcome 2 The rate of progress in CT images.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Akira 1993 {published data only}
    1. Akira M, Higashihara T, Sakatani M, Hara H. Diffuse panbronchiolitis: follow‐up CT examination. Radiology 1993;189:559‐62. - PubMed

References to studies excluded from this review

Hyeon 1997 {published data only}
    1. Hyeon KC, Jung KW, Hun JS, Gyu YC, Whan KY, Seog HD, et al. Long‐term follow‐up of patients with diffuse panbronchiolitis after erythromycin therapy. Journal of Korea Medical Science 1997;53:414‐9.
Kadota 2003 {published data only}
    1. Kadota J, Mukae H, Ishii H, Nagata T, Kaida H, Tomono K, et al. Long‐term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis. Respiratory Medicine 2003;97:844‐50. - PubMed
Kadota 2004 {published data only}
    1. Kadota J‐I, Mukae H, Tomono K, Kohno S, Nasu M. Efficacy of long‐term macrolide antibiotic therapy in patients with diffuse panbronchiolitis: comparison between HLA‐B54‐positive and ‐negative cases. International Journal of Antimicrobial Agents 2004;24:550‐4. - PubMed
Kadota 2005 {published data only}
    1. Kadota J‐I, Mukae H, Mizunoe S, Kishi K, Tokimatsu I, Nagai H, et al. Long‐term macrolide antibiotic therapy in the treatment of chronic small airway disease clinically mimicking diffuse panbronchiolitis. Internal Medicine 2005;44:200‐6. - PubMed
Kudoh 1984 {published data only}
    1. Kudoh S, Kimura H, Uetake M, Hirayama T, Hisaya K, Teratani Y, et al. Clinical effect of low‐dose long‐term administration of macrolides on diffuse panbronchiolitis. Japanese Journal of Thoracic Disease 1984;22(Suppl):254.
Kudoh 1998 {published data only}
    1. Kudoh S, Azuma A, Yamamoto M, Izumi T, Ando M. Improvement of survival in patients with diffuse panbronchiolitis treated with low‐dose erythromycin. American Journal of Respiratory and Critical Care Medicine 1998;157:1829‐32. - PubMed
Nagai 1991 {published data only}
    1. Nagai H, Shishido H, Yoneda R, Yamaguchi E, Tamura A, Kurashima A. Long‐term low‐dose administration of erythromycin to patients with diffuse panbronchiolitis. Respiration 1991;58:145‐9. - PubMed
Sato 1993 {published data only}
    1. Sato A, Hayakawa H, Suda T. Ofloxacin and erythromycin in the management of diffuse panbronchiolitis. Drugs 1993:399‐400.
Shirai 1997 {published data only}
    1. Shirai R, Abe K, Yoshinaga M, Ishimatsu Y, Matsubara Y, Kawakami K, et al. Analysis of cases allowed to cease erythromycin therapy for diffuse panbronchiolitis ‐ comparative study between patients with cessation of the therapy and patients continuing the therapy. Journal of the Japanese Association for Infectious Diseases 1997;71:1155‐61. - PubMed
Yamamoto 1990a {published data only}
    1. Yamamoto M, Kondo A, Tamura M, Izumi T, Ina Y, Noda M. Long‐term therapeutic effects of erythromycin and new quinolone antibacterial agents on diffuse panbronchiolitis. Japanese Journal of Thoracic Diseases 1990;28:1305‐13. - PubMed
Yamamoto 1992 {published data only}
    1. Yamamoto M. Therapeutic effects of erythromycin on diffuse panbronchiolitis. A multicenter, double blind placebo‐controlled trial. Sarcoidosis 1992;Suppl 1:633‐6.

Additional references

Azuma 2006
    1. Azuma A, Kudoh S. Diffuse panbronchiolitis in East Asia. Respirology 2006;11:249‐61. - PubMed
Bai 2000
    1. Bai H, Zhao J, Liao M. Diffuse panbronchiolitis: a case report. Chinese Journal of Practical Internal Medicine 2000;20(3):162.
Chen 2000
    1. Chen BZ, Xiang XD, Chen P. A case of diffuse panbronchiolitis. Bulletin of Hunan Medical University 2000;25(6):534. - PubMed
Chen 2007
    1. Chen X, Liu S, Wang J, Ni Y. Diffuse panbronchiolitis: six cases report. Fujian Medical Journal 2007;29(6):42‐3.
Desai 1989
    1. Desai SJ, Gephardt GN, Stoller JK. Diffuse panbronchiolitis preceding ulcerative colitis. Chest 1989;95:1342‐4. - PubMed
Ding 2007
    1. Ding K, Liu M‐B, Wu JL, Ma H‐Q, Fang X‐Y, Miao GB, et al. Diffuse panbronchiolitis in China: analysis of 45 cases. Chinese Medical Journal 2007;120:2046‐8. - PubMed
Fitzgerald 1996
    1. Fitzgerald JE, King TE Jr, Lynch DA, Tuder RM, Schwarz MI. Diffuse panbronchiolitis in the United States. American Journal of Respiratory and Critical Care Medicine 1996;154:497‐503. - PubMed
Giamarellos‐Bourboulis 2008
    1. Giamarellos‐Bourboulis EJ. Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators. International Journal of Antimicrobial Agents 2008;31:12‐20. - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Homma 1983
    1. Homma H, Yamanaka A, Tanimoto S, Tamura M, Chijimatsu Y, Kira S, et al. Diffuse panbronchiolitis. A disease of the transitional zone of the lung. Chest 1983;83:63‐9. - PubMed
Hou 1998
    1. Hou X, Yuan X, Chen L. Diffuse panbronchiolitis: a case report. Journal of Yunyang Medical College 1998;17(2):106.
Hu 1996
    1. Hu H, Liu Y, Cai Z, Chen L. A case of diffuse panbronchiolitis. Chinese Medical Journal 1996;109(12):949‐52. - PubMed
Hu 2009
    1. Hu S, Luo Y. Diffuse panbronchiolitis: a case report and review of the literature. Jiangxi Medical Journal 2009;44(2):137‐9.
Izumi 1983
    1. Izumi T, Doi O, Nobechi A, Homma Y, Kino N, Nakata K, et al. Nation‐wide survey of diffuse panbronchiolitis. Annual report on the study of interstitial lung disease in 1982. Grant‐in Aid from the Ministry of Health and Welfare of Japan. Tokyo, 1983:3‐41.
Izumi 1991
    1. Izumi T. Diffuse panbronchiolitis. Chest 1991;100:596‐7. - PubMed
Kobayashi 1995
    1. Kobayashi H, Takeda H, Sakayori S, Kawakami Y, Otsuka Y, Tamura M, et al. Study on azithromycin in treatment of diffuse panbronchiolitis. Kansenshogaku Zasshi 1995;69:711‐22. - PubMed
Kudoh 1987
    1. Kudoh S, Uetake T, Hagiwara K, Hirayama M, Hus LH, Kimura H, et al. Clinical effect of low‐dose long‐term erythromycin chemotherapy on diffuse panbronchiolitis. Japanese Journal of Thoracic Diseases 1987;25:632‐42. - PubMed
Lefebvre 2011
    1. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Li 2007
    1. Li H, Huang J, Li X, Yu H, Zhao L, He G. Clinical analysis of twenty four patients with diffuse panbronchiolitis. Suzhou University Journal of Medical Science 2007;27(3):449‐52.
Liu 1999
    1. Liu Y, Hu H, Zhang J. A clinical trial of 14 and 15 membered macrolides in treating six cases of diffuse panbronchiolitis. Chinese Journal of Internal Medicine 1999;38(9):622‐4. - PubMed
Liu 2006
    1. Liu M, Ding K, Wu J, Ma H, Fang X, Miao G, et al. Analysis of 45 patients with diffuse panbronchiolitis in China. Chinese Journal of Medicine 2006;41(11):39‐40.
López‐Boado 2008
    1. López‐Boado YS, Rubin BK. Macrolides as immunomodulatory medications for the therapy of chronic lung diseases. Current Opinion in Pharmacology 2008;8:286‐91. - PubMed
Nakamura 1999
    1. Nakamura H, Fujishima S, Inoue T, Ohkubo Y, Soejima K, Waki Y, et al. Clinical and immunoregulatory effects of roxithromycin therapy for chronic respiratory tract infection. European Respiratory Journal 1999;13:1371‐9. - PubMed
Nakata 2000
    1. Nakata K, Taguchi Y, Kudoh S. Therapeutic guidelines for DPB. Annual report on the study of diffuse lung disease in 1999. Grant‐in aid from the Ministry of Health and Welfare of Japan. Tokyo, 2000:111.
Poletti 1990
    1. Poletti V, Patelli M, Poletti G, Bertanti T, Spiga L. Diffuse panbronchiolitis observed in an Italian. Chest 1990;98:515‐6. - PubMed
Randhawa 1991
    1. Randhawa P, Hoagland MH, Yousem SA. Diffuse panbronchiolitis in North America. Report of three cases and review of the literature. American Journal of Surgical Pathology 1991;15:43‐7. - PubMed
RevMan 2014 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Sandrini 2003
    1. Sandrini A, Balter MS, Chapman KR. Diffuse panbronchiolitis in a Caucasian man in Canada. Canadian Respiratory Journal 2003;10:449‐51. - PubMed
Tamaoki 1995
    1. Tamaoki J, Takeyama K, Tagaya E, Konno K. Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory tract infections. Antimicrobial Agents and Chemotherapy 1995;39:1688‐90. - PMC - PubMed
Tan 2006
    1. Tan T, Liu W, Jiang L. Clinical analysis of 43 cases of diffuse panbronchiolitis. China Journal of Modern Medicine 2006;16:2538‐9.
Xue 2002
    1. Xue F, Mi J. Diffuse panbronchiolitis: a case report. Shanxi Medical Journal 2002;31(3):278.
Yamamoto 1990b
    1. Yamamoto M, Kudoh S, Ina Y, Tamura A. Clinical efficacy of erythromycin for patients with diffuse panbronchiolitis – a double blind study. Saishin Igaku 1990;45:103‐8.
Yamanaka 1969
    1. Yamanaka A, Saiki S, Tamura S, Saito K. Problems in chronic obstructive bronchial diseases, with special reference to diffuse panbronchiolitis. Naika 1969;23:442‐51. - PubMed
Zai 2009
    1. Zai H, Huo Z. Clinical analysis of twenty three patients with diffuse panbronchiolitis. Clinical Medicine of China 2009;25(1):51‐4.

References to other published versions of this review

Yang 2009
    1. Yang M, Dong BR, Lin X, Wu HM. Macrolides for diffuse panbronchiolitis. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD007716] - DOI - PubMed
Yang 2010
    1. Yang M, Dong BR, Lu J, Lin X, Wu HM. Macrolides for diffuse panbronchiolitis. Cochrane Database of Systematic Reviews 2010, Issue 12. [DOI: 10.1002/14651858.CD007716.pub2] - DOI - PubMed
Yang 2013
    1. Yang M, Dong BR, Lu J, Lin X, Wu HM. Macrolides for diffuse panbronchiolitis. Cochrane Database of Systematic Reviews 2013, Issue 2. [DOI: 10.1002/14651858.CD007716.pub3] - DOI - PubMed

Publication types

MeSH terms

Supplementary concepts